BioCentury
ARTICLE | Financial News

to-BBB raises EUR 10M in series C

July 1, 2014 1:30 AM UTC

Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series C round from new and existing investors. The company's investors include Aescap Venture; Antea Participaties; Jonghoud International; and the Industrial Bank of Taiwan Management.

to-BBB combines existing drugs with its delivery platform to enhance drug delivery across the blood-brain barrier. Lead product 2B3-101 -- a pegylated liposomal doxorubicin conjugated with glutathione -- is in Phase IIa testing to treat primary brain tumors and brain metastases. ...